Article History
Accepted: 12 February 2024
First Online: 29 February 2024
Competing interests
: S.K. has received honoraria for lectures from Chugai Pharmaceutical and Merck Sharp & Dohme (MSD) outside the submitted work. H.N. has received research funding and honoraria for lectures from Bristol Myers Squibb, Chugai Pharmaceutical, MSD and Ono Pharmaceuticals; honoraria for lectures from Amgen; and research funding from Asahi-Kasei, Astellas Pharma, BD Japan, Daiichi Sankyo, Debiopharma, Fujifilm, Kyowa Kirin, Oncolys BioPharma, Sisco Research Laboratories (SRL), Sumitomo Dainippon Pharma, Sysmex, Taiho Pharmaceutical and Zenyaku Kogyo outside this work. H.N. is also a board member and a founder of ARC Therapies and a scientific adviser of LTZ Therapeutics. K.I. declares no competing interests.